Traduction de «well-directed information can improve » (Néerlandais → Français) :

But, on the other hand, clear and well-directed information can improve public knowledge on this issue, thus strengthening the protective factors.
Mais par ailleurs, une information claire et bien dirigée peut augmenter la compréhension que le grand public a de cette problématique et par là, renforcer les facteurs de protection.

According to the WHO, eight domains have been identified in which this type of action can be taken, i.e. making employers more aware of mental health issues, identifying the common goals and positive aspects of the job, creating a balance between job demand and professional competence, training social competence, improving the psychosocial climate in the work place, giving advice to employees, improving the ability to work as well as strategies for early rehabilitation, improving work opportunities.
Selon l’OMS, huit domaines d’action ont été recensés à cet égard: sensibilisation accrue de l’employeur aux problèmes de santé mentale; identification de buts communs et d’aspects positifs du travail; équilibrage entre la demande d’emploi et les compétences professionnelles; formation aux aptitudes sociales; développement du climat psychosocial du lieu de travail; conseils dispensés aux travailleurs; amélioration de la capacité de travail et stratégies de réadaptation précoce, amélioration des opportunités d’emploi.

This improvement is a direct consequence of the strong sales of A (H1N1) pandemic vaccines as well as programs in the divisions to significantly reduce cash conversion cycles.
Ce bond est la conséquence directe des ventes considérables de vaccins contre la pandémie de grippe A (H1N1) ainsi que des programmes mis en place dans les divisions visant à réduire notablement les cycles d’exploitation.

- Level 2: Improving the competence of society’s key figures Training sessions on depression and suicide are offered to various occupational groups who, without having any specific training, come into contact with individuals suffering from depression or suicidal thoughts, viz. pharmacists, teachers, PMS (Psycho-Medico-Social) centres, pastoral workers, hospital staff, police agents, prison officers, etc. These occupational groups can contribute to providing better support to these individuals, as well as to the early detection of problems and possible guidance.
Niveau 2: développement des compétences des figures clés dans la société Des sessions de formation sur la dépression et le suicide sont offertes à différents groupes professionnels qui entrent en contact avec des personnes souffrant d’une dépression ou d’idées suicidaires, mais qui n’ont pas eu de formation spécifique. A ce groupe appartiennent des pharmaciens, des professeurs, des centres PMS, des agents pastoraux, le personnel d’hôpitaux, des agents de police, des agents pénitentiaires, etc. Ces professionnels peuvent contribuer à un meilleur soutien pour ces personnes, détection précoce de problèmes et orientation éventuelle.

On www.gachet.be, general practitioners as well as other health professionals can find information on critical incidents (e.g. a patient’s attempted suicide), a list of recommended foreign texts, a list of useful addresses and even a real expert helpdesk which answers additional questions.
Sur www.gachet.be les généralistes et les autres intervenants peuvent trouver des explications sur des incidents critiques (p.ex. une tentative de suicide d’un patient), une liste de textes étrangers recommandés, une liste d’adresses utiles, et même un vrai helpdesk d’experts qui répondent à des questions supplémentaires.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.